Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamidronic Acid SCHEMBL570525 | 0.98 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11106361 | 0.94 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831396 | 0.88 | FDPS (0.76) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL429804 | 0.86 | FDPS (0.79) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570526 | 0.85 | FDPS (0.78) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL8850008 | 0.84 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11037738 | 0.84 | FDPS (0.61) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5608824 | 0.84 | FDPS (0.70) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL506809 | 0.83 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL4260287 | 0.83 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4802096-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20070015736-A1 | Pharmaceutical products comprising bisphosphonates | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-01-18 | — | — | US | claimed |
| EP-1663314-A2 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | Novartis AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005025551-A2 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | claimed |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20080254089-A1 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-10-16 | — | — | US | disclosed |
| WO-2008040763-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPHONATES | NOVARTIS AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20070015736-A1 | Pharmaceutical products comprising bisphosphonates | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-01-18 | — | — | US | disclosed |
| EP-1107974-B1 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-08-02 | — | — | EP | disclosed |
| EP-1663314-A2 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-0800397-B1 | BONE MASS ANABOLIC COMPOSITION COMPRISING OLPADRONATE | GADOR SA (AR) | 2006-04-05 | — | — | EP | disclosed |
| US-20050119230-A1 | Pharmaceutical products comprising bisphosphonated | GLAUSCH ALEXANDRA (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005025551-A2 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| EP-0891979-B1 | A crystalline form of monohydrate monosodium salt of the N,N-Dimethyl-3-amino-1-Hydroxypropan-1,1-Disphosphonic acid and the procedure for its preparation | GADOR SA (AR) | 2004-10-20 | — | — | EP | disclosed |
| US-5885973-A | Bone mass anabolic composition comprising olpadronate | GADOR, S.A. (AR) | 1999-03-23 | — | — | US | disclosed |
| EP-0891979-A1 | A crystalline form of monohydrate monosodium salt of the N,N-Dimethyl-3-amino-1-Hydroxypropan-1,1-Disphosphonic acid and the procedure for its preparation | GADOR S.A. (AR) | 1999-01-20 | — | — | EP | disclosed |
| US-4711880-A | FOR CALCIUM AND PHOSPHATE METABOLISM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4639338-A | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119230-A1 | Pharmaceutical products comprising bisphosphonated | BPGM, P2RY6, PIK3CA | FDPS 270/4885PDE3A 3019/4885LMNA 3801/4885 |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | PTEN, PPIP5K2, ACP3 | FDPS 324/4885PDE3A 1080/4885LMNA 3944/4885 |
| US-20070015736-A1 | Pharmaceutical products comprising bisphosphonates | PIK3CA, PTH1R, PPA1 | FDPS 332/4885PDE3A 3012/4885LMNA 4374/4885 |
| US-20080254089-A1 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | PTH1R, PIK3CA, PPIP5K2 | FDPS 296/4885PDE3A 2833/4885LMNA 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.